Apogee Therapeutics, Inc.
NASDAQ:APGEBiotechnology
+$1.05 today
- Market cap
- $8.36B
- Beta
- 0.62
- P/E (TTM)
- -22.7
- EPS (TTM)
- -$3.94
Volume 0.00M
Average 0.97M
APGE Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Apogee Therapeutics, Inc.NASDAQ: APGE
Other Current Liabilities · Q2 FY2026 · quarter ended Jun 2026
Other current liabilities remains negative
Q2 FY2026 other current liabilities was $0, compared with $13.69M a year earlier. Over 3 fiscal years it compounded at +92.2% a year.
Context
- Other current liabilities amounted to 0.0% of total assets at the end of Q2 FY2026, down 2.1 pp from a year earlier.
- Other current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether other current liabilities keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 3.66M USD
- Year-over-year change
- -83.6%
- 3-year CAGR
- +92.2%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.66M | -83.6% |
| FY2024 | 2024-12-31 | 22.36M | +30.4% |
| FY2023 | 2023-12-31 | 17.15M | +3229.5% |
| FY2022 | 2022-12-31 | 515K | — |
Other Current Liabilities vs competitors
How APGE compares with its peers on the latest reported figures
- Peers report in different currencies, so other current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -100.0% is the 6th highest of 7, against a peer median of +83.8%.
- Other current liabilities amounts to 0.0% of total assets for APGE, versus a peer median of 1.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International | Dec 2025 | CN¥276.84M CNY | — | +361.2% | 7.0% |
| Sep 2026 | $45.31M USD | +583.4% | +273.6% | 4.3% | |
| Mar 2026 | $25.92M USD | +834.9% | +64.4% | 4.0% | |
| Mar 2026 | $17M USD | -83.1% | — | 1.3% | |
| Jun 2026 | $16.84M USD | +250.8% | +20.4% | 1.6% | |
| Sep 2026 | $1.1M USD | — | -75.4% | 0.1% | |
| Sep 2026 | $106K USD | -99.5% | +54.8% | 0.0% | |
| Jun 2026 | $0 USD | -100.0% | +92.2% | 0.0% | |
| Jun 2026 | $0 USD | — | +130.1% | 0.0% | |
IRONDisc Medicine, Inc. | Sep 2026 | $0 USD | -100.0% | +95.4% | 0.0% |
| Peer median (excluding APGE) | — | +83.8% | +79.9% | 1.3% | |
Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Apogee Therapeutics, Inc.
NASDAQ:APGE
Intrinsic Alpha fair value
Locked
Current Price
$135.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.